AU2021244594A1 - T cell receptors - Google Patents

T cell receptors Download PDF

Info

Publication number
AU2021244594A1
AU2021244594A1 AU2021244594A AU2021244594A AU2021244594A1 AU 2021244594 A1 AU2021244594 A1 AU 2021244594A1 AU 2021244594 A AU2021244594 A AU 2021244594A AU 2021244594 A AU2021244594 A AU 2021244594A AU 2021244594 A1 AU2021244594 A1 AU 2021244594A1
Authority
AU
Australia
Prior art keywords
amino acid
tcr
chain
acid substitutions
tcra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021244594A
Other languages
English (en)
Inventor
Jasdeep MANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2021244594A1 publication Critical patent/AU2021244594A1/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. Request for Assignment Assignors: 2SEVENTY BIO, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021244594A 2020-03-27 2021-03-26 T cell receptors Pending AU2021244594A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000800P 2020-03-27 2020-03-27
US63/000,800 2020-03-27
PCT/US2021/024370 WO2021195503A1 (en) 2020-03-27 2021-03-26 T cell receptors

Publications (1)

Publication Number Publication Date
AU2021244594A1 true AU2021244594A1 (en) 2022-12-01

Family

ID=77890524

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021244594A Pending AU2021244594A1 (en) 2020-03-27 2021-03-26 T cell receptors

Country Status (11)

Country Link
US (1) US20230124640A1 (https=)
EP (1) EP4126924A4 (https=)
JP (2) JP7738007B2 (https=)
KR (1) KR20220160040A (https=)
CN (1) CN115485294A (https=)
AU (1) AU2021244594A1 (https=)
BR (1) BR112022019380A2 (https=)
CA (1) CA3177181A1 (https=)
IL (1) IL296827A (https=)
MX (1) MX2022012062A (https=)
WO (1) WO2021195503A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361794B2 (en) * 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
CN102876715B (zh) 2012-09-05 2014-07-23 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267B (zh) 2012-09-19 2014-04-02 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
CA3225252A1 (en) * 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies

Also Published As

Publication number Publication date
KR20220160040A (ko) 2022-12-05
IL296827A (en) 2022-11-01
CN115485294A (zh) 2022-12-16
CA3177181A1 (en) 2021-09-30
BR112022019380A2 (pt) 2022-11-29
JP2025172113A (ja) 2025-11-20
EP4126924A1 (en) 2023-02-08
EP4126924A4 (en) 2024-04-24
JP7738007B2 (ja) 2025-09-11
JP2023519868A (ja) 2023-05-15
US20230124640A1 (en) 2023-04-20
MX2022012062A (es) 2023-01-11
WO2021195503A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2020267641B2 (en) Engineered T cells
JP2025172113A (ja) Ｔ細胞受容体
JP2022537159A (ja) 癌を治療するための組成物および方法
US20240342215A1 (en) Engineered t cell receptors fused to binding domains from antibodies
EP4038103A1 (en) Dimerizing agent regulated immunoreceptor complexes
EP3894436A1 (en) Dimerizing agent regulated immunoreceptor complexes
WO2020227475A1 (en) Cll-1 targeted immunotherapies
KR20230053650A (ko) Bcma 키메라 항원 수용체
EP3966251A1 (en) Cd33 targeted immunotherapies
WO2020227481A1 (en) Cd123 targeted immunotherapies
EA052725B1 (ru) Т-клеточные рецепторы
WO2022099176A1 (en) Aml targeted immunotherapies
EA049270B1 (ru) Сконструированные т-клетки

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: REGENERON PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): 2SEVENTY BIO, INC.